Notícias e Atividades da Mersana Therapeutics

Mersana Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Mersana Therapeutics é uma empresa listada sob o símbolo MRSN (US).

Veja o organograma con seus 29 executivos principais

Biografias mais buscadas da Mersana Therapeutics

• Martin Huber, Director, President and Chief Executive Officer
• Kristen Hege, Director
• Anna Protopapas, Director

Criar um alerta
para seguir os movimentos de executivos da Mersana Therapeutics.

Mersana Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of Verve Therapeutics  (publicado em 17 de junho de 2025).
• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Mersana Therapeutics

• Press Releases - Mersana Therapeutics
• Mersana Therapeutics to Present Preclinical Data from Immunosynthen STING-Agonist ADC Platform at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting - Mersana Therapeutics
• Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study - Mersana Therapeutics
• Mersana Therapeutics to Present Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study at the 2020 ESMO Virtual Congress - Mersana Therapeutics
• Mersana Therapeutics to Present at Upcoming Investor Conferences - Mersana Therapeutics
• Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Mersana Therapeutics
• Mersana Therapeutics Appoints Chuck Miller as Senior Vice President of Regulatory Affairs - Mersana Therapeutics
• Mersana Therapeutics Receives FDA Fast Track Designation for XMT-1536 for the Treatment of Patients with Platinum-resistant Ovarian Cancer - Mersana Therapeutics
• Mersana Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update - Mersana Therapeutics
• Mersana Therapeutics to Present at Upcoming Investor Conferences - Mersana Therapeutics
• View more press releases Close

Redes sociais sobre Mersana Therapeutics

• Mersana Therapeutics na Wikipedia, Google News e Yahoo Finance
• Mersana Therapeutics na LinkedIn, Twitter e YouTube